

ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

STARTVAC emulsion for injection for cattle

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

One dose (2 ml) contains:

Active substances:

Escherichia coli J5 inactivated

> 50 RED₆₀*

Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC)

> 50 RED₈₀**

* RED₆₀: Rabbit effective dose in 60% of the animals (serology).

** RED₈₀: Rabbit effective dose in 80% of the animals (serology).

Adjuvant:

Liquid paraffin

18.2 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Benzyl alcohol	21 mg
Sorbitan monooleate	
Polysorbate 80	
Sodium alginate	
Calcium chloride, dihydrate	
Simeticone	
Water for injections	

Ivory-coloured homogeneous emulsion.

3. CLINICAL INFORMATION

3.1 Target species

Cattle (cows and heifers).

3.2 Indications for use for each target species

For herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by *Staphylococcus aureus*, coliforms and coagulase-negative staphylococci.

The full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection.

3.3 Contraindications

None.

3.4 Special warnings

The whole herd should be immunised.

Immunisation has to be considered as one component in a complex mastitis control program that addresses all important udder health factors (e.g. milking technique, dry-off and breeding management, hygiene, nutrition, housing, bedding, cow comfort, air and water quality, health monitoring) and other management practices.

Vaccinate healthy animals only.

3.5 Special precautions for use

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:

Not applicable.

3.6 Adverse events

Cattle (cows and heifers):

Very rare (< 1 animal / 10 000 animals treated, including isolated reports):	Injection site swelling ¹ , injection site pain ² Elevated temperature ³ Anaphylactic-type reaction ⁴
--	---

¹Slight to moderate transient local reactions (up to 5 cm² on average) may occur after the administration of one dose, which disappears within 1 or 2 weeks at most.

²Slight to moderate transient local reactions that spontaneously subsides in a maximum of 4 days.

³A mean transient increase in body temperature of about 1 °C, in some cows up to 2 °C, may occur in the first 24 hours after injection.

⁴Such reactions may occur in some sensitive animals which might be life-threatening. Under these circumstances, appropriate and rapid symptomatic treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See the package leaflet for respective contact details.

3.7 Use during pregnancy, lactation or lay

Pregnancy and lactation:

Can be used during pregnancy and lactation.

3.8 Interaction with other medicinal products and other forms of interaction

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

3.9 Administration routes and dosage

Intramuscular use.

The injections should be preferably administered on the alternate sides of the neck. Allow the vaccine to reach a temperature of 15 °C to 25 °C before administration. Shake before use.

Administer one dose (2 ml) by deep intramuscular injection in the neck muscles at 45 days before the expected parturition date and 1 month thereafter administer a second dose (at least 10 days before calving). A third dose should be administered 2 months thereafter.

The full immunisation program should be repeated with each gestation.

3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No adverse reactions other than those mentioned in section 3.6 were observed after the administration of a double dose of vaccine.

3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance

Not applicable.

3.12 Withdrawal periods

Zero days.

4. IMMUNOLOGICAL INFORMATION

4.1 ATCvet code : QI02AB17.

To stimulate active immunity against *Staphylococcus aureus*, coliforms and coagulase-negative staphylococci.

5. PHARMACEUTICAL PARTICULARS

5.1 Major incompatibilities

Do not mix with any other veterinary medicinal product.

5.2 Shelf life

Shelf life of the veterinary medicinal product as packaged for sale: 18 months.

Shelf life after first opening the immediate packaging: 10 hours stored at 15 °C to 25 °C.

5.3 Special precautions for storage

Store and transport refrigerated (2 °C – 8 °C).

Protect from light.

Do not freeze.

5.4 Nature and composition of immediate packaging

Type I colourless glass vials of 3, 10 and 50 ml.

Polyethylene (PET) vials of 10, 50 and 250 ml.

The vials are closed with a rubber stopper and aluminium cap.

Pack sizes:

Cardboard box with 1 glass vial of 1 dose.

Cardboard box with 10 glass vials of 1 dose.

Cardboard box with 20 glass vials of 1 dose.

Cardboard box with 1 glass vial of 5 doses.

Cardboard box with 10 glass vials of 5 doses.

Cardboard box with 1 glass vial of 25 doses.

Cardboard box with 10 glass vials of 25 doses.

Cardboard box with 1 PET vial of 5 doses.

Cardboard box with 1 PET vial of 25 doses.

Cardboard box with 1 PET vial of 125 doses.

Not all pack sizes may be marketed.

5.5 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

6. NAME OF THE MARKETING AUTHORISATION HOLDER

LABORATORIOS HIPRA S.A.

7. MARKETING AUTHORISATION NUMBER(S)

EU/2/08/092/001-010

8. DATE OF FIRST AUTHORISATION

Date of first authorisation: 11/02/2009

9. DATE OF THE LAST REVISION OF THE SUMMARY OF THE PRODUCT CHARACTERISTICS

{DD/MM/YYYY}

10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the [Union Product Database](https://medicines.health.europa.eu/veterinary) (<https://medicines.health.europa.eu/veterinary>).

ANNEX II

OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION

None

ANNEX III
LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Cardboard boxes, PET vial (250 ml)

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

STARTVAC emulsion for injection for cattle

2. STATEMENT OF ACTIVE SUBSTANCES

One dose (2 ml) contains:

E. coli J5 inactivated > 50 RED₆₀ (Rabbit effective dose in 60% of the animals (serology)).

S. aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC)
> 50 RED₈₀ (In 80% of the animals).

Liquid paraffin: 18.2 mg

Benzyl alcohol: 21 mg.

3. PACKAGE SIZE

1 vial of 1 dose (2 ml)

10 vials of 1 dose (2 ml)

20 vials of 1 dose (2 ml)

1 vial of 5 doses (10 ml)

10 vials of 5 doses (10 ml)

1 vial of 25 doses (50 ml)

10 vials of 25 doses (50 ml)

1 vial of 125 doses (250 ml)

125 doses (250 ml)

4. TARGET SPECIES

Cattle (cows and heifers).

5. INDICATIONS**6. ROUTES OF ADMINISTRATION**

Intramuscular use.

7. WITHDRAWAL PERIODS

Withdrawal period: Zero days.

8. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within a 10-hour period, stored at 15 °C–25 °C.

9. SPECIAL STORAGE PRECAUTIONS

Store and transport refrigerated.
Protect from light.
Do not freeze.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

LABORATORIOS HIPRA, S.A.

14. MARKETING AUTHORISATION NUMBERS

EU/2/08/092/001 1 glass vial 1 dose
EU/2/08/092/002 10 glass vials 1 dose
EU/2/08/092/003 20 glass vials 1 dose
EU/2/08/092/004 1 glass vial 5 doses
EU/2/08/092/005 10 glass vials 5 doses
EU/2/08/092/006 1 glass vial 25 doses
EU/2/08/092/007 10 glass vials 25 doses
EU/2/08/092/008 1 PET vial of 5 doses
EU/2/08/092/009 1 PET vial of 25 doses
EU/2/08/092/010 1 PET vial of 125 doses

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**PET vials (10 ml, 50 ml) and glass vials (2 ml, 10 ml, 50 ml)****1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

STARTVAC

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

One dose contains:

E. coli J5 inactivated; *S. aureus* (CP8) strain SP 140 inactivated.**3. BATCH NUMBER**

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

Once opened, use within a 10-hour period, stored at 15 °C–25 °C.

5. PACKAGE SIZE

1 dose (2 ml)

5 doses (10 ml)

25 doses (50 ml)

B. PACKAGE LEAFLET

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

STARTVAC emulsion for injection for cattle

2. Composition

One dose (2 ml) contains:

Escherichia coli (J5) inactivated

> 50 RED₆₀*

Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime associated antigenic complex (SAAC)

> 50 RED₈₀**

* RED₆₀: Rabbit effective dose in 60% of the animals (serology).

** RED₈₀: Rabbit effective dose in 80% of the animals (serology).

Liquid paraffin: 18.2 mg

Benzyl alcohol: 21 mg.

Ivory-coloured homogeneous emulsion.

3. Target species

Cattle (cows and heifers).

4. Indications for use

For herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by *Staphylococcus aureus*, coliforms and coagulase-negative staphylococci.

The full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection.

5. Contraindications

None.

6. Special warnings

Special warnings:

The whole herd should be immunised.

Immunisation has to be considered as one component in a complex mastitis control program that addresses all important udder health factors (e.g. milking technique, dry-off and breeding management, hygiene, nutrition, housing, bedding, cow comfort, air and water quality, health monitoring) and other management practices.

Vaccinate healthy animals only.

Special precautions for safe use in the target species:

Not applicable.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this veterinary medicinal product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose:

No adverse reactions other than those mentioned in section “Adverse reactions” were observed after the administration of a double dose of vaccine.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

7. Adverse events

Cattle (cows and heifers):

Very rare (< 1 animal / 10 000 animals treated, including isolated reports):
Injection site swelling ¹ , injection site pain ²
Elevated temperature ³
Anaphylactic-type reaction (severe allergic reaction) ⁴

¹Slight to moderate transient local reactions (up to 5 cm² on average) may occur after the administration of one dose, which disappears within 1 or 2 weeks at most.

²Slight to moderate transient local reactions that spontaneously subsides in a maximum of 4 days.

³A mean transient increase in body temperature of about 1 °C, in some cows up to 2 °C, may occur in the first 24 hours after injection.

⁴Such reactions may occur in some sensitive animals which might be life-threatening. Under these circumstances, appropriate and rapid symptomatic treatment should be administered.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing

authorisation holder using the contact details at the end of this leaflet, or via your national reporting system: {national system details}

8. Dosage for each species, routes and method of administration

Intramuscular use. The injections should be preferably administered on the alternate sides of the neck.

Administer one dose (2 ml) by deep intramuscular injection in the neck muscles at 45 days before the expected parturition date and 1 month thereafter administer a second dose (at least 10 days before calving). A third dose should be administered 2 months thereafter.
The full immunisation program should be repeated with each gestation.

9. Advice on correct administration

Allow the vaccine to reach a temperature of 15 °C to 25 °C before administration. Shake before use.

10. Withdrawal periods

Zero days.

11. Special storage precautions

Keep out of the sight and reach of children.
Store and transport refrigerated (2 °C – 8 °C).
Protect from light.
Do not freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the cardboard box and the label after Exp. The expiry date refers to the last day of that month.
Shelf life after first opening the immediate packaging: 10 hours stored at 15 °C to 25 °C.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. Marketing authorisation numbers and pack sizes

Marketing authorisation numbers: EU/2/08/092/001-010

Pack sizes:

- Cardboard box with 1, 10 and 20 glass vials of 1 dose.

- Cardboard box with 1 and 10 glass vials of 5 doses.
- Cardboard box with 1 and 10 glass vials of 25 doses.
- Cardboard box with 1 PET vial of 5 doses.
- Cardboard box with 1 PET vial of 25 doses.
- Cardboard box with 1 PET vial of 125 doses.

Not all pack sizes may be marketed.

15. Date on which the package leaflet was last revised

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available in the [Union Product Database \(https://medicines.health.europa.eu/veterinary\)](https://medicines.health.europa.eu/veterinary).

16. Contact details

Marketing authorisation holder and manufacturer responsible for batch release and contact details to report suspected adverse reactions:

LABORATORIOS HIPRA, S.A.
Avda. la Selva, 135
17170 AMER (Girona) SPAIN
TEL: +34 972 43 06 60

Local representatives and contact details to report suspected adverse reactions:

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

België/Belgique/Belgien

HIPRA BENELUX NV
Nieuwewandeling 62
9000 Gent
BELGIUM
Tel: +32 09 2964464

Lietuva

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
ISPANIJA
Tel: +34 972 43 06 60

Република България

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
ИСПАНИЯ
Тел: +34 972 43 06 60

Luxembourg/Luxemburg

HIPRA BENELUX NV
Nieuwewandeling 62
9000 Gent
BELGIUM
Tel: +32 09 2964464

Česká republika

HIPRA SLOVENSKO, s.r.o.
Zochova 5,
811 03 Bratislava,
SLOVENSKO
Tel: +421 02 32 335 223

Magyarország

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPANYOLORSZÁG
Tel: +34 972 43 06 60

Danmark

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPANIEN
Tel: +34 972 43 06 60

Deutschland

HIPRA DEUTSCHLAND GmbH
Am Wehrhahn 28-30
40211 Düsseldorf
DEUTSCHLAND
Tel: +49 211 698236 – 0

Eesti

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
HISPAANIA
Tel: +34 972 43 06 60

Ελλάδα

HIPRA ΕΛΛΑΣ Α.Ε.
Λεωφ. Αθηνών 80 & Μηριόνου 2-4,
104 41 Κολωνός - ΑΘΗΝΑ - ΕΛΛΑΣ
Τηλ: +30 210 4978660

España

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
ESPAÑA
Tel: +34 972 43 06 60

France

HIPRA FRANCE
7 rue Roland Garros, Batiment H
44700 - Orvault -
FRANCE
Tél: +33 02 51 80 77 91

Hrvatska

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
ŠPANJOLSKA
Tel: +34 972 43 06 60

Ireland

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPAIN
Tel: +34 972 43 06 60

Malta

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPANJA
Tel: +34 972 43 06 60

Nederland

HIPRA BENELUX NV
Nieuwewandeling 62
9000 Gent
BELGIUM
Tel: +32 09 2964464

Norge

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPANIA
Tlf: +34 972 43 06 60

Österreich

HIPRA DEUTSCHLAND GmbH
Am Wehrhahn 28-30
40211 Düsseldorf
DEUTSCHLAND
Tel: +49 211 698236 – 0

Polska

HIPRA POLSKA Sp.z.o.o.
Ul. Wincentego Rzymowskiego 31
02-697 Warszawa - POLSKA
Tel: +48 22 642 33 06

Portugal

ARBUSET, Produtos Farmacêuticos e Sanitários
De Uso Animal, Lda
Portela de Mafra e Fontainha - Abrunheira
2665 – 191 Malveira - PORTUGAL
Tel: +351 219 663 450

România

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPANIA
Tel: +34 972 43 06 60

Slovenija

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
ŠPANIJA
Tel: +34 972 43 06 60

Ísland

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPÁNN
Sími: +34 972 43 06 60

Italia

Hipra Italia S.r.l.
Enrico Mattei, 2
25030 Coccaglio (BS)
ITALIA
Tel: +39 030 7241821

Κύπρος

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
ΙΣΠΑΝΙΑ
Τηλ: +34 972 43 06 60

Latvija

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPĀNIJA
Tel. +34 972 43 06 60

Slovenská republika

HIPRA SLOVENSKO, s.r.o.
Zochova 5,
811 03 Bratislava,
SLOVENSKO
Tel: +421 02 32 335 223

Suomi/Finland

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
ESPANJA
Puh/Tel: +34 972 43 06 60

Sverige

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPANIEN
Tel. +34 972 43 06 60

United Kingdom (Northern Ireland)

LABORATORIOS HIPRA, S.A.
Avda. La Selva 135
17170 Amer (Girona)
SPAIN
Tel: +34 972 43 06 60